全文获取类型
收费全文 | 727176篇 |
免费 | 52001篇 |
国内免费 | 1340篇 |
专业分类
耳鼻咽喉 | 9408篇 |
儿科学 | 23773篇 |
妇产科学 | 17905篇 |
基础医学 | 113119篇 |
口腔科学 | 20646篇 |
临床医学 | 66723篇 |
内科学 | 139020篇 |
皮肤病学 | 16730篇 |
神经病学 | 51117篇 |
特种医学 | 26634篇 |
外国民族医学 | 76篇 |
外科学 | 107623篇 |
综合类 | 15232篇 |
现状与发展 | 2篇 |
一般理论 | 183篇 |
预防医学 | 53819篇 |
眼科学 | 16651篇 |
药学 | 55712篇 |
3篇 | |
中国医学 | 2378篇 |
肿瘤学 | 43763篇 |
出版年
2019年 | 5758篇 |
2018年 | 8190篇 |
2017年 | 6355篇 |
2016年 | 7122篇 |
2015年 | 7895篇 |
2014年 | 10728篇 |
2013年 | 16136篇 |
2012年 | 21530篇 |
2011年 | 22516篇 |
2010年 | 13285篇 |
2009年 | 12452篇 |
2008年 | 20943篇 |
2007年 | 22439篇 |
2006年 | 22868篇 |
2005年 | 21449篇 |
2004年 | 20925篇 |
2003年 | 19821篇 |
2002年 | 19356篇 |
2001年 | 37135篇 |
2000年 | 37748篇 |
1999年 | 31082篇 |
1998年 | 8139篇 |
1997年 | 6893篇 |
1996年 | 7181篇 |
1995年 | 6846篇 |
1994年 | 6277篇 |
1993年 | 5776篇 |
1992年 | 23494篇 |
1991年 | 23481篇 |
1990年 | 22812篇 |
1989年 | 22508篇 |
1988年 | 20463篇 |
1987年 | 19830篇 |
1986年 | 18899篇 |
1985年 | 17718篇 |
1984年 | 12997篇 |
1983年 | 11003篇 |
1982年 | 6111篇 |
1979年 | 11815篇 |
1978年 | 8338篇 |
1977年 | 7007篇 |
1976年 | 6744篇 |
1975年 | 7413篇 |
1974年 | 8688篇 |
1973年 | 8327篇 |
1972年 | 7807篇 |
1971年 | 7300篇 |
1970年 | 7024篇 |
1969年 | 6421篇 |
1968年 | 5922篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Carnitine palmitoyltransferase deficiency in a patient with severe psychomotor retardation 总被引:1,自引:0,他引:1
H Suzuki Y Hirayama S Hirano R Takahashi I Nonaka H Sugie N Sugiyama 《No to hattatsu. Brain and development》1991,23(1):93-97
A 13-year-old girl who had severe brain damage due to unknown prenatal cause presented rhabdomyolysis triggered by a mild viral infection. Her muscle biopsy revealed mild variation in fiber size and type 2 fiber atrophy without excess lipid storage. Biochemical analysis of the biopsied material showed decreased carnitine palmitoyltransferase (CPT) activity (15% of the control). Serum and urinary carnitine levels were normal. Skeletal muscle CT scanning showed multiple low density spots. The patient was diagnosed as having CPT deficiency. She recovered from rhabdomyolysis without renal failure after a month with conservative therapy. CPT deficiency is usually found in young healthy persons. This is the first case report of CPT deficiency which presented severe psychomotor retardation since neonatal period. 相似文献
993.
994.
995.
N Sato 《Nihon Geka Gakkai zasshi》1986,87(12):1511-1525
The relationship between nutritional status and muscle strength was examined in 73 patients with gastrointestinal carcinoma preoperatively. Nutritional status was assessed by measuring various nutritional parameters. Muscle strength was determined by measurements of %grip strength and respiratory muscle strength expressed as %maximal expiratory and inspiratory pressure (%MEP and %MIP). The results were as follows: %GS was significantly low in the patients who showed low values in body weight (%ideal body weight: %IBW), mid-arm muscle circumference (%AMC), serum albumin (Alb), serum prealbumin (PA), total peripheral lymphocyte count (TLC), and/or nutritional surgical risk index (NRI). %MEP was significantly low in the patients who showed low values in %IBW, %AMC, triceps skin fold, Alb, PA, retinol binding protein, NRI, and/or nutritional assessment index (NAI). %MIP was significantly low in the patients who showed low values in %IBW, %AMC, creatinine height index, Alb, PA, NRI, and/or NAI. %MEP and %MIP were significantly correlated with %GS. Preoperative %GS value was significantly low in the esophageal cancer patients with postoperative pulmonary complications. It was suggested that %GS was a simple and useful nutritional parameter for detecting depletion of the muscle mass and visceral proteins, for respiratory muscle strength, and for functional capacity of muscle. 相似文献
996.
997.
H Enomoto J Yoshida N Kageyama R Ueda T Kato K Ota 《Gan to kagaku ryoho. Cancer & chemotherapy》1986,13(5):1953-1961
Human TNF was detected fairly recently and at present the anti-tumor activity of human recombinant TNF is being examined against various malignant tumors of human origin. In the present study, we report the anti-tumor activity of recombinant human TNF against human malignant glioma cell lines in vitro and in vivo, in addition to its combined effects with HuIFN-beta. The in vitro study was conducted as follows. Thirteen human glioma cell lines were exposed to 100 U/ml TNF, 1,000 IU/ml HuIFN-beta, or both, and the suppression rate was calculated on days 3, 5 and 7. In the in vivo study, nude mice carrying a human glioma cell line, KMS II, in the subcutaneous tissues were divided into groups and drugs were administered intratumorally as described below. 1) control, 2) TNF 5,000 U single administration, 3) TNF 5,000 U, intermittently administered (once/week for two weeks), 4) TNF 5,000 U, continuously administered (3/week for two weeks), 5) HuIFN-beta 50 X 10(4) IU (3/week for two weeks), and 6) combination of 4) with 5). Results of the in vitro study revealed some suppressive effects on proliferation of tumor cells on day 7 in all 13 glioma cell lines examined with 100 U/ml TNF. And also, especially in 8 of 13 cell lines, the suppression rate was more than 30%. The suppressive effects of TNF were augmented by combined use of HuIFN-beta in all cell lines, giving a range of suppression of 67.8 to 99.3%. The in vivo study revealed that the mean tumor weight ratios (control = 100%) on day 19 (the end of the experiment) were as follows; single administration of TNF: 41.3%, intermittent: 46.7%, continuous: 26.7%, HuIFN-beta: 65.9%, combination: 18.5%. Statistical analysis disclosed significant suppressive effects on tumor proliferation between the control group and 3 TNF-administered groups (single, intermittent, and continuous) and that suppression in the continuously administered group was more severe in comparison with the group given single administration. Moreover, it was suggested that combination therapy with TNF and Hu IFN-beta was more effective than a single therapy with TNF only or HuIFN-beta only. From the results described above, it was found that human recombinant TNF had some cytotoxic effects against human malignant gliomas in vitro and in vivo, although the degree of cytotoxicity was not always higher in comparison with the effects of TNF. 相似文献
998.
Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer 总被引:2,自引:0,他引:2
J N Ingle J E Krook S J Green T P Kubista L K Everson D L Ahmann M N Chang H F Bisel H E Windschitl D I Twito 《Journal of clinical oncology》1986,4(2):178-185
A randomized clinical trial was performed to compare the efficacy of bilateral oophorectomy with that of tamoxifen at a dose of 10 mg twice daily in premenopausal women with metastatic breast cancer, and to examine the efficacy of each as a crossover treatment. Initial treatment responses were seen in ten of 27 patients (37%) treated with oophorectomy and seven of 26 patients (27%) treated with tamoxifen. The difference was not statistically significant. Crossover responses were seen in five of 15 patients (33%) treated with oophorectomy, including three responses in ten prior tamoxifen nonresponders; and two of 18 patients (11%) treated with tamoxifen. Time to progression distributions were not significantly different during initial treatment, and no significant differences in survival were noted. Thus, there was no overall disadvantage to the use of tamoxifen as opposed to oophorectomy as initial hormonal therapy, and a failure to respond to tamoxifen did not preclude a response to subsequent oophorectomy. Exploratory data analysis within subsets indicated consistent differential treatment effects in the visceral dominant patients. Of the 16 such patients treated with oophorectomy, eight (50%) experienced objective responses but there were no responses in the 14 patients treated with tamoxifen. In the nine visceral dominant crossover patients who had not responded to initial tamoxifen, three (33%) subsequently responded to oophorectomy. Time to progression distributions within the visceral dominant subset appeared to be better for the patients treated initially with oophorectomy. However, one must be very cautious in drawing conclusions from exploratory subset analyses, especially with the small sample size. Further studies would be required to test any hypothesis of differential organ site responsiveness. 相似文献
999.
1000.
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS 总被引:2,自引:0,他引:2
I. FUCHS† M. FROSSARD† A. SPIEL E. RIEDMÜLLER† A. N. LAGGNER† B. JILMA 《Journal of thrombosis and haemostasis》2006,4(12):2547-2552
BACKGROUND: Platelet hyperfunction contributes to acute coronary syndromes (ACS). Thus, we hypothesized that platelet function under high shear stress predicts recurrent ACS during long-term follow-up of ACS patients. PATIENTS AND METHODS: Consecutive ACS patients (n = 208) were prospectively followed-up for an average of 28 months. Platelet function was measured with the platelet function analyzer (PFA-100; Dade Behring, Marburg, Germany) at baseline for collagen/adenosine diphosphate closure times (CADP-CT) and for collagen/epinephrine closure times (CEPI-CT) after infusion of a uniform dose of 250 mg aspirin. RESULTS: Of the conventional risk factors, only the prevalence of diabetes was higher in ACS patients with re-events. However, use of clopidogrel and use of beta blockers were also slightly lower in patients with re-events (P < 0.05). The unadjusted risk hazard ratio (HR) for re-events was 3.3 [95% confidence interval (95% CI): 1.4-7.4; P = 0.005] in those patients with the shortest CADP-CT values (lowest quartile). Similarly, the risk was 2.0-fold higher (95% CI: 1.1-3.6; P = 0.02) in ACS patients with CEPI-CT < 300 s as compared with CEPI-CT >or = 300 s. Inclusion of diabetes, clopidogrel and beta blockers in a multivariate Cox regression model enhanced the predictive value of CEPI-CT (HR: 2.7). Inclusion of von Willebrand factor levels did not alter the HR for recurrent ACS (HR: 2.1; 95% CI: 1.1-5.2; P = 0.03) for CEPI-CT < 300 s, but reduced the HR for CADP-CT (HR: 2.8, 95% CI: 0.8-9.8; P = 0.11). CONCLUSION: Shortened CT values reflect biologically relevant platelet hyperfunction in patients with ACS because they predict recurrent ACS. 相似文献